Ocumetics Technology Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OTCFF research report →
Price Chart
About the company
Specializing in research and product development, Ocumetics Technology Corp. engineers and manufactures a range of optical lenses. A flagship offering is the Bionic Lens, an innovative, expandable intraocular lens designed to be precisely placed within the eye's natural lens capsule, thereby removing the necessity for traditional corrective eyewear.
- CEO
- Dean E. Burns
- IPO
- 2021
- Employees
- 3
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on OTCFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $17.69M
- P/E
- -6.95
- PEG
- 0.11
- P/S
- 0.00
- P/B
- -12.36
- EV/EBITDA
- -6.56
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 175.10%
- ROIC
- 6889.70%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-108,774+19.0%
- Op Income
- $-5,364,296
- Net Income
- $-5,373,327-77.8%
- EPS
- $-0.04-58.7%
- OCF Growth
- -38.5%
- FCF Growth
- -38.8%
- 52W High
- $0.92
- 52W Low
- $0.26
- 50D MA
- $0.33
- 200D MA
- $0.36
- Beta
- 0.34
- RSI (14)
- 45
- Avg Volume
- 4.43K
No earnings-call transcripts are available for OTCFF yet.
- Free Float
- 62.2%
- Shares Outstanding
- 58.91M
- Float Shares
- 36.67M
Our OTCFF coverage
Recent articles, reports, and earnings notes.
No research on OTCFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OTCFF report →Ocumetics Provides Summary of Group One Patient Clinical Progress
thenewswire.com · Sep 17
Ocumetics Announces Initiation of Patient Recruitment for Upcoming Group Two Human Clinical Surgeries
thenewswire.com · Sep 8
Ocumetics Completes Manufacturing of Next Generation Solid State Accommodating Intraocular Lenses for Upcoming Group Two First in Human Clinical Surgeries
thenewswire.com · Aug 31
Ocumetics Announces Completion of Third and Final Tranche of Unit Private Placement
thenewswire.com · Aug 24
Ocumetics Announces Completion of Second Tranche of Unit Private Placement
thenewswire.com · Jul 31
Ocumetics Announces Upsizing of Unit Private Placement
thenewswire.com · Jul 30
Ocumetics Announces Completion of First Tranche of Unit Private Placement
thenewswire.com · Jul 29
Ocumetics Announces Corporate and Operational Update as Positive Six-Month Clinical Results Advance Next Phase of First-in-Human Study
thenewswire.com · Jul 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.